208 related articles for article (PubMed ID: 36197966)
1. Assessment of cholesterol homeostasis in the living human brain.
Haider A; Zhao C; Wang L; Xiao Z; Rong J; Xia X; Chen Z; Pfister SK; Mast N; Yutuc E; Chen J; Li Y; Shao T; Warnock GI; Dawoud A; Connors TR; Oakley DH; Wei H; Wang J; Zheng Z; Xu H; Davenport AT; Daunais JB; Van RS; Shao Y; Wang Y; Zhang MR; Gebhard C; Pikuleva I; Levey AI; Griffiths WJ; Liang SH
Sci Transl Med; 2022 Oct; 14(665):eadc9967. PubMed ID: 36197966
[TBL] [Abstract][Full Text] [Related]
2. Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases.
Petrov AM; Pikuleva IA
Neurotherapeutics; 2019 Jul; 16(3):635-648. PubMed ID: 31001737
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.
Mast N; Saadane A; Valencia-Olvera A; Constans J; Maxfield E; Arakawa H; Li Y; Landreth G; Pikuleva IA
Neuropharmacology; 2017 Sep; 123():465-476. PubMed ID: 28655608
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional and post-translational changes in the brain of mice deficient in cholesterol removal mediated by cytochrome P450 46A1 (CYP46A1).
Mast N; Lin JB; Anderson KW; Bjorkhem I; Pikuleva IA
PLoS One; 2017; 12(10):e0187168. PubMed ID: 29073233
[TBL] [Abstract][Full Text] [Related]
5. CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer's disease.
Lerner AJ; Arnold SE; Maxfield E; Koenig A; Toth ME; Fortin B; Mast N; Trombetta BA; Denker J; Pieper AA; Tatsuoka C; Raghupathy S; Pikuleva IA
Alzheimers Res Ther; 2022 Dec; 14(1):198. PubMed ID: 36581878
[TBL] [Abstract][Full Text] [Related]
6. New Therapeutic Targets for Brain Function and Disease.
van Lier JE
J Med Chem; 2020 Jun; 63(12):6474-6476. PubMed ID: 31845585
[TBL] [Abstract][Full Text] [Related]
7. Brain cholesterol and Alzheimer's disease: challenges and opportunities in probe and drug development.
Ahmed H; Wang Y; Griffiths WJ; Levey AI; Pikuleva I; Liang SH; Haider A
Brain; 2024 May; 147(5):1622-1635. PubMed ID: 38301270
[TBL] [Abstract][Full Text] [Related]
8. CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease.
Djelti F; Braudeau J; Hudry E; Dhenain M; Varin J; Bièche I; Marquer C; Chali F; Ayciriex S; Auzeil N; Alves S; Langui D; Potier MC; Laprevote O; Vidaud M; Duyckaerts C; Miles R; Aubourg P; Cartier N
Brain; 2015 Aug; 138(Pt 8):2383-98. PubMed ID: 26141492
[TBL] [Abstract][Full Text] [Related]
9. The potential of CYP46A1 as a novel therapeutic target for neurological disorders: An updated review of mechanisms.
Alavi MS; Karimi G; Ghanimi HA; Roohbakhsh A
Eur J Pharmacol; 2023 Jun; 949():175726. PubMed ID: 37062503
[TBL] [Abstract][Full Text] [Related]
10. CYP46A1-dependent and independent effects of efavirenz treatment.
Mast N; El-Darzi N; Petrov AM; Li Y; Pikuleva IA
Brain Commun; 2020; 2(2):fcaa180. PubMed ID: 33305262
[TBL] [Abstract][Full Text] [Related]
11. Cholesterol 24-hydroxylase: Brain cholesterol metabolism and beyond.
Moutinho M; Nunes MJ; Rodrigues E
Biochim Biophys Acta; 2016 Dec; 1861(12 Pt A):1911-1920. PubMed ID: 27663182
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 27A1 Deficiency and Regional Differences in Brain Sterol Metabolism Cause Preferential Cholestanol Accumulation in the Cerebellum.
Mast N; Anderson KW; Lin JB; Li Y; Turko IV; Tatsuoka C; Bjorkhem I; Pikuleva IA
J Biol Chem; 2017 Mar; 292(12):4913-4924. PubMed ID: 28190002
[TBL] [Abstract][Full Text] [Related]
13. Unbiased insights into the multiplicity of the CYP46A1 brain effects in 5XFAD mice treated with low dose-efavirenz.
Mast N; Butts M; Pikuleva IA
J Lipid Res; 2024 Jun; 65(6):100555. PubMed ID: 38719151
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic implications of altered cholesterol homeostasis mediated by loss of CYP46A1 in human glioblastoma.
Han M; Wang S; Yang N; Wang X; Zhao W; Saed HS; Daubon T; Huang B; Chen A; Li G; Miletic H; Thorsen F; Bjerkvig R; Li X; Wang J
EMBO Mol Med; 2020 Jan; 12(1):e10924. PubMed ID: 31777202
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice.
Mast N; Li Y; Linger M; Clark M; Wiseman J; Pikuleva IA
J Biol Chem; 2014 Feb; 289(6):3529-38. PubMed ID: 24352658
[TBL] [Abstract][Full Text] [Related]
16. Brain Acetyl-CoA Production and Phosphorylation of Cytoskeletal Proteins Are Targets of CYP46A1 Activity Modulation and Altered Sterol Flux.
Mast N; Petrov AM; Prendergast E; Bederman I; Pikuleva IA
Neurotherapeutics; 2021 Jul; 18(3):2040-2060. PubMed ID: 34235635
[TBL] [Abstract][Full Text] [Related]
17. CYP46A1 Activation by Efavirenz Leads to Behavioral Improvement without Significant Changes in Amyloid Plaque Load in the Brain of 5XFAD Mice.
Petrov AM; Lam M; Mast N; Moon J; Li Y; Maxfield E; Pikuleva IA
Neurotherapeutics; 2019 Jul; 16(3):710-724. PubMed ID: 31062296
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol redistribution triggered by CYP46A1 gene therapy improves major hallmarks of Niemann-Pick type C disease but is not sufficient to halt neurodegeneration.
Nunes MJ; Carvalho AN; Reis J; Costa D; Moutinho M; Mateus J; Mendes de Almeida R; Brito S; Risso D; Nunes S; Castro-Caldas M; Gama MJ; Rodrigues CMP; Xapelli S; Diógenes MJ; Cartier N; Chali F; Piguet F; Rodrigues E
Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):166993. PubMed ID: 38142760
[TBL] [Abstract][Full Text] [Related]
19. Mapping of the Allosteric Site in Cholesterol Hydroxylase CYP46A1 for Efavirenz, a Drug That Stimulates Enzyme Activity.
Anderson KW; Mast N; Hudgens JW; Lin JB; Turko IV; Pikuleva IA
J Biol Chem; 2016 May; 291(22):11876-86. PubMed ID: 27056331
[TBL] [Abstract][Full Text] [Related]
20. Increased Acetylcholine Levels and Other Brain Effects in 5XFAD Mice after Treatment with 8,14-Dihydroxy Metabolite of Efavirenz.
Mast N; Li Y; Pikuleva IA
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
